Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonazoid CEUS for Sentinel Lymph Node Detection in Gynecologic Cancers
NCT05105087Phase 1Completed
- Sponsor
- Thomas Jefferson University
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonazoid in Cervical Cancer (CC), vaginal cancer and vulvar cancer, sponsored by Thomas Jefferson University. Primary endpoint: Number of Sentinel Lymph Nodes (SLNs) Identified by Lymphosonography as Well as Blue Dye or Positron Emission Tomography (PET)-Computed Tomography (CT) at 30 minutes. Started Apr 2022; status: completed.
02
Drugs
sonazoid
03
Conditions
Cervical Cancer (CC)vaginal cancervulvar cancer
Beyond the preview
Go deeper on NCT05105087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105087.